 |
|
Systemic Amiloride Inhibits Experimentally Induced Neovascularization
Robert L. Avery, MD;
Thomas B. Connor, Jr, MD;
Mahmood Farazdaghi
Arch Ophthalmol. 1990;108(10):1474-1476.
Abstract
• Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. Neovascularization was induced in rabbit corneas via local implantation of prostaglandin E, pellets prepared in a slow-release polymer. Animals received daily intraperitoneal injections of 30 mg of amiloride, or an equivalent volume of saline solution for 5 days; both were well tolerated without severe untoward effect. Neovascular response, as documented by corneal photographs, was evaluated after 5 days of injections. The area of induced corneal neovascularization was decreased by 55% in animals receiving amiloride when compared with controls. Thus, amiloride and similar compounds may prove useful in the study and management of neovascularization.
Author Affiliations
From the The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital, Baltimore, Md.
Footnotes
Accepted for publication July 19, 1990.
Reprint requests to the Wilmer Ophthalmological Institute, B-23 Wilmer Bldg, The Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21205 (Dr Avery).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Basic Fibroblast Growth Factor–Induced Angiogenic Phenotype in Mouse Endothelium : A Study of Aortic and Microvascular Endothelial Cell Lines
Bastaki et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:454-464.
ABSTRACT
| FULL TEXT
New Activity of Spironolactone: Inhibition of Angiogenesis In Vitro and In Vivo
Klauber et al.
Circulation 1996;94:2566-2571.
ABSTRACT
| FULL TEXT
|
